Sector Category: Life Sciences
![Ventyx Biosciences Ventyx Biosciences](https://www.newscienceventures.com/wp-content/uploads/2020/11/VentyxBio-RGB-Web-300x85.png)
Ventyx Biosciences
Developing selective inhibitors of TYK2 for autoimmune diseases.
Read More![Morrow Morrow](https://www.newscienceventures.com/wp-content/uploads/2020/11/Logo_m-300x98.jpg)
![NorthSea Therapeutics NorthSea Therapeutics](https://www.newscienceventures.com/wp-content/uploads/2020/11/Logo_NorthSea-300x111.png)
NorthSea Therapeutics
Focused on the development of first-in-class therapeutics for NASH and other metabolic, inflammatory and fibrotic diseases.
Read More![Seahorse Bioscience Seahorse Bioscience](https://www.newscienceventures.com/wp-content/uploads/2020/11/seahorsewhite.png)
Seahorse Bioscience
Acquired by Agilent Technologies. Developer of tools for measuring cell metabolism.
Read More![K2M K2M](https://www.newscienceventures.com/wp-content/uploads/2020/11/k2mwhite.png)
![FlowCardia FlowCardia](https://www.newscienceventures.com/wp-content/uploads/2020/11/flowcardiawhite.png)
FlowCardia
Acquired by C.R. Bard. Developer of endovascular devices for the treatment of coronary and peripheral CTO.
Read More![Dezima Dezima](https://www.newscienceventures.com/wp-content/uploads/2020/11/dezimawhite.png)
![Conor Medsystems Conor Medsystems](https://www.newscienceventures.com/wp-content/uploads/2020/11/conorwhite.png)
Conor Medsystems
Acquired by Johnson & Johnson. Focused on the development of drug-eluting stents to treat coronary artery disease.
Read More![Ception Ception](https://www.newscienceventures.com/wp-content/uploads/2020/11/ceptionwhite.png)
![Biovex Biovex](https://www.newscienceventures.com/wp-content/uploads/2020/11/biovexwhite.png)
![Akarna Therapeutics Akarna Therapeutics](https://www.newscienceventures.com/wp-content/uploads/2020/11/akarna_blue_org_mag_resized37.jpeg)
Akarna Therapeutics
Acquired by Allergan. Focused on the development of a small molecule therapy for the treatment of NASH.
Read More![Vascular Therapies Vascular Therapies](https://www.newscienceventures.com/wp-content/uploads/2020/11/vt98.jpg)
Vascular Therapies
Focused on the development of a drug-based solution to reduce the failure rate of AV Fistulas in dialysis patients.
Read More